Considering the strong ability of activated macrophages to secrete inflammatory cytokines like IL-1β, using PI3K inhibitors could potentially reduce asthma symptoms by boosting the protective effects of GLCCI1 in these cells. This evidence concerns the gene GLCCI1 and asthma.